Literature DB >> 27697315

Comparison of short-term clinical outcomes between transanal and laparoscopic total mesorectal excision for the treatment of mid and low rectal cancer: A meta-analysis.

W Xu1, Z Xu1, H Cheng1, J Ying1, F Cheng1, W Xu1, J Cao1, J Luo2.   

Abstract

AIM: The objective of this meta-analysis was to evaluate the feasibility, safety, and short-term clinical outcomes of transanal total mesorectal excision (TaTME) comparing with laparoscopy total mesorectal excision (LapTME) for mid and low rectal cancer.
METHODS: Relevant studies were searched from the databases of Pubmed, Embase, and the Cochrane Library. The qualities of all of the included studies were evaluated using Newcastle-Ottawa Scale (NOS). The synthesized outcomes were pooled using fixed-effects models or random-effects models, which weighted the odds ratio (OR) or mean difference (MD) with 95% confidence intervals (95% CI). A funnel plot was used to evaluate the publication bias.
RESULTS: Seven original studies including 209 TaTME patients and 257 LapTME patients with rectal cancer met the inclusion criteria in this meta-analysis. Compared with LapTME, TaTME showed a longer CRM, lower rate of positive CRM, complete TME rate, and less operative time. There were no significant differences in the outcomes of the harvested lymph nodes, distal margin distance, hospital stay, intraoperative complications, anastomotic leakage, postoperative complications, reoperation, readmission, or conversion between the TaTME group and the LapTME group.
CONCLUSIONS: Compared with LapTME, TaTME is a feasible and safe approach for patients with mid and low rectal cancer. In addition, TaTME showed a better short-term clinical outcomes, such as a longer CRM, lower risk of positive CRM, higher complete quality of TME rate, and shorter operative duration. Further prospective studies with long-term follow-up are required.
Copyright © 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Laparoscopy; Meta-analysis; Rectal cancer; Total mesorectal excision; Transanal

Mesh:

Year:  2016        PMID: 27697315     DOI: 10.1016/j.ejso.2016.09.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  16 in total

1.  Transanal total mesorectal excision (TaTME): single-centre early experience in a selected population.

Authors:  Michele De Rosa; Fabio Rondelli; Marcello Boni; Fabio Ermili; Walter Bugiantella; Lorenzo Mariani; Graziano Ceccarelli; Antonio Giuliani
Journal:  Updates Surg       Date:  2018-11-08

2.  Response to commentary on "Transanal total mesorectal excision (taTME) for rectal cancer: a systematic review and meta-analysis of oncological and perioperative outcomes compared with laparoscopic total mesorectal excision".

Authors:  B Ma; P Gao; Z Wang
Journal:  Tech Coloproctol       Date:  2017-02-08       Impact factor: 3.781

Review 3.  Summary of Oncologic and Functional Outcomes.

Authors:  Roel Hompes; Marta Penna
Journal:  Clin Colon Rectal Surg       Date:  2020-04-28

4.  Effect of transanal total mesorectal excision for rectal cancer: comparison of short-term outcomes with laparoscopic and open surgeries.

Authors:  Sharaf Karim Perdawood; Benjamin Sejr Thinggaard; Maya Xania Bjoern
Journal:  Surg Endosc       Date:  2017-11-02       Impact factor: 4.584

5.  Quality of Life After Surgery for Rectal Cancer: a Comparison of Functional Outcomes After Transanal and Laparoscopic Approaches.

Authors:  Maya Xania Bjoern; Sarah Nielsen; Sharaf Karim Perdawood
Journal:  J Gastrointest Surg       Date:  2019-01-02       Impact factor: 3.452

6.  Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid-low rectal cancer.

Authors:  Gulsen Atasoy; Naciye Cigdem Arslan; Funda Dinc Elibol; Ozgul Sagol; Funda Obuz; Selman Sokmen
Journal:  Surg Today       Date:  2018-06-30       Impact factor: 2.549

Review 7.  Recent advances in the management of rectal cancer: No surgery, minimal surgery or minimally invasive surgery.

Authors:  Joseph M Plummer; Pierre-Anthony Leake; Matthew R Albert
Journal:  World J Gastrointest Surg       Date:  2017-06-27

Review 8.  Evolution of transanal total mesorectal excision for rectal cancer: From top to bottom.

Authors:  Sameh Hany Emile; F Borja de Lacy; Deborah Susan Keller; Beatriz Martin-Perez; Sadir Alrawi; Antonio M Lacy; Manish Chand
Journal:  World J Gastrointest Surg       Date:  2018-03-27

9.  Short-term efficacy of natural orifice specimen extraction surgery for low rectal cancer.

Authors:  Jun-Hong Hu; Xing-Wang Li; Chen-Yu Wang; Jun-Jie Zhang; Zheng Ge; Bing-Hui Li; Xu-Hong Lin
Journal:  World J Clin Cases       Date:  2019-01-26       Impact factor: 1.337

10.  Transanal total mesorectal excision (TaTME) versus laparoscopic TME for MRI-defined low rectal cancer: a propensity score-matched analysis of oncological outcomes.

Authors:  Sapho Xenia Roodbeen; Marta Penna; Hugh Mackenzie; Miranda Kusters; Andrew Slater; Oliver M Jones; Ian Lindsey; Richard J Guy; Chris Cunningham; Roel Hompes
Journal:  Surg Endosc       Date:  2018-10-22       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.